Journal Management System
 
Home  |   Add your Journal  |   Features  |   Journal List
Author Login | Reviewer Login | Editor Login
Search  

Medical Archives
Periodical of AVICENA, d.o.o., Sarajevo
Journal Home Page
ISSN: 0350-199X (Print)
ISSN: 1986-5961 (Online)
Language: [ English ]  
News / Announcements

  » Volume 68, Issue 5
      pp. 300-363
  » Volume 68, Issue 4
      pp. 228-293
  » Volume 68, Issue 3
      pp. 156-222
  » Volume 68, Issue 2
      pp. 76-146
  » Volume 68, Issue 1
      pp. 4-70

 

Open Access

Original Research



Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection

Damir Aganovic, Alden Prcic, Benjamin Kulovac, Osman Hadziosmanovic.

Cited by (1)

Abstract
Aim: Establish the main differences in the prostate volume, prostate specific antigen density (PSAD), number of biopsy samples in patients with primarily or rebiopsy detected prostate cancer. Materials and methods: In the 2007-2009 period, at the KCUS Urology Clinic, there were 379 TRUS guided prostate biopsies in 323 patients with known prostate volume. The total of 56 patients (17.3%) underwent the first rebiopsy, primarily due to precancerous lesions. The mean prostate volume, ranges of prostate size, PSAT, PSAD and the number of biopsy samples were analysed retrospectively, and the main characteristics in patients with primarily and rebiopsy diagnosed Pca were evaluated as well. Results: The first biopsy cancer detection rate was 29.6% (112/379). The rebiopsy detection rate was 30.3%. There was no statistically significant difference in the prostate volume and the number of biopsy samples among the total number of patients with prostate cancer against the group with benign (suspected) findings. There was a higher Pca detection rate in patients with the prostate volume <40 cm3 and 40-60 cm3, against the group with the prostate volume >60 cm3. PSAD was significantly higher in patients with PCa (0.24 vs. 0.18; p=0.013). The total of 27.2% of the patients with negative biopsy findings and 48% of the patients with diagnosed Pca had PSAD >0.15. PSAD showed sensitivity and specificity in prostate cancer detection of 50% and 75%, with PPV of 48%. Furthermore, the patients with PSAD >0.15 had a higher Gleason score versus the patients with PSAD <0.15 (6.7 ± 2.4 vs. 5.9 ± 1.7; p <0.003). A comparison of the main characteristics in patients with primarily and rebiopsy detected prostate cancer gave a statistically significant difference only in the number of biopsy samples (10.9 vs. 14.1, p <.0000). Conclusion: Patients with a smaller prostate volume, lower PSAD and a higher number of biopsy samples in rebiopsy have a higher chance of prostate cancer detection. PSAD carries a higher specificity in rebiopsy decision, and a higher PSAD is related to a higher Gleason score.

Key words: PCa, prostate biopsy, prostate volume, PSAD.



REFERENCES
1. Catalona WJ, Smith DS, Ratliff TL. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 24 (17): 1156-1161.
[DOI via Crossref]    [Pubmed]   

2. Schröder FH, van der Maas P, Beemsterboer P, Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 1998; 90(23): 1817-1823.
[
DOI via Crossref]   

3. Carvalhal GF, Smith DS, Mager DE. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol. 1999; 161(3): 835-839.
[
DOI via Crossref]   

4. Urdiales-Ortiz A, Camarena-Reynoso H, Cantellano-Orozco M, Morales-Montor J, Pacheco-Gahbler C, Calderón-Ferro F. Nine and twelve specimens from prostate biopsy and their impact on cancer detection: a comparative study, Rev Mex Urol. 2010; 70(4): 206-210.


5. Presti JC, Kane JC, Shinohara K, Carroll PR: Neoplasms of the Prostate Gland, in Tanagho, EA, McAninch JW, Smith’s General Urology, 17th edition, The McGraw-Hill Co, USA, 2008.


6. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005; 48: 546-551
[
DOI via Crossref]    [Pubmed]   

7. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level [DOI via Crossref]    [Pubmed]   

8. Berger AP, Volgger H, Rogatsch H, et al. Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens. Prostate. 2002; 53: 241-245.
[
DOI via Crossref]    [Pubmed]   

9. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol. 1994; 152: 2037-2042.
[
Pubmed]   

10. Brawer MK: Prostate-specific antigen: Current status. CA Cancer J Clin. 1999; 49: 264-281.
[
DOI via Crossref]   

11. Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: A decade of discovery. What we have learned and where we are going. J Urol. 1999; 162: 293-306.
[
DOI via Crossref]   

12. Kuriyama M, Kawada Y, Arai Y, Maeda H, Egava S, Koshiba K, et al. Significance of free to total PSA ratio in men slightly elevated serum PSA levels: a cooperative study. Jpn J Clin Oncol. 1998; 28: 661-665.
[
DOI via Crossref]    [Pubmed]   

13. Ficarra V, Novella G, Novara G, Galfano A, Pea M, Martignoni G, Artibani W, The Potential Impact of Prostate Volume in the Planning of Optimal Number of Cores in the Systematic Transperineal Prostate Biopsy, Eur Urol, 2005; 48: 932-37.
[
DOI via Crossref]    [Pubmed]   

14. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan Jr ED. The influence of prostate size on cancer detection. Urology. 1995; 46(6): 831.836.


15. Aref I, Eapen L, Agboola O, Cross P. Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy. The British Journal of Radiology. 1998; 71: 868-871.
[
Pubmed]   

16. Campos-Fernandes JL, Bastien L, Nicolaiev N, Robert G, Terry S, Vacherot F, Salmon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A. Prostate Cancer Detection Rate in Patients with Repeated Extended 21.Sample Needle Biopsy. Eur Urol. 2009; 55: 600-609.
[
DOI via Crossref]    [Pubmed]   

17. Finne P, Auvinen A, Aro J, Juusela H, Määtänen L, Rannikko S, Hakama M, Tammela TLJ, Stenman UK. Estimation of Prostate Cancer Risk on the Basis of Total and Free Prostate-Specific Antigen, Prostate Volume and Digital Rectal Examination. Eur Urol. 2002; 41: 619-27.
[
DOI via Crossref]   

This Article Cited By the following articles

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
Prostate Int 2013; 1(3): 102.

1
 

How to Cite this Article
Pubmed Style

Aganovic D, Prcic A, Kulovac B, Hadziosmanovic O. Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection . Med Arh. 2012; 66(1): 41-44. doi:10.5455/medarh.2012.66.41-44



Web Style

Aganovic D, Prcic A, Kulovac B, Hadziosmanovic O. Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection . www.scopemed.org/?mno=16924 [Access: October 30, 2014]. doi:10.5455/medarh.2012.66.41-44



AMA (American Medical Association) Style

Aganovic D, Prcic A, Kulovac B, Hadziosmanovic O. Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection . Med Arh. 2012; 66(1): 41-44. doi:10.5455/medarh.2012.66.41-44



Vancouver/ICMJE Style

Aganovic D, Prcic A, Kulovac B, Hadziosmanovic O. Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection . Med Arh. (2012), [cited October 30, 2014]; 66(1): 41-44. doi:10.5455/medarh.2012.66.41-44



Harvard Style

Aganovic, D., Prcic, A., Kulovac, B. & Hadziosmanovic, O. (2012) Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection . Med Arh, 66 (1), 41-44. doi:10.5455/medarh.2012.66.41-44



Turabian Style

Aganovic, Damir, Alden Prcic, Benjamin Kulovac, and Osman Hadziosmanovic. 2012. Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection . Medical Archives, 66 (1), 41-44. doi:10.5455/medarh.2012.66.41-44



Chicago Style

Aganovic, Damir, Alden Prcic, Benjamin Kulovac, and Osman Hadziosmanovic. "Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection ." Medical Archives 66 (2012), 41-44. doi:10.5455/medarh.2012.66.41-44



MLA (The Modern Language Association) Style

Aganovic, Damir, Alden Prcic, Benjamin Kulovac, and Osman Hadziosmanovic. "Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection ." Medical Archives 66.1 (2012), 41-44. Print. doi:10.5455/medarh.2012.66.41-44



APA (American Psychological Association) Style

Aganovic, D., Prcic, A., Kulovac, B. & Hadziosmanovic, O. (2012) Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection . Medical Archives, 66 (1), 41-44. doi:10.5455/medarh.2012.66.41-44



Submit your manuscript
Register
Abstracting & Indexing
Instructions for Authors
Editorial Board
Aims & Scope
About this Journal
Sign up for TOC

ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Damir Aganovic
Articles by Alden Prcic
Articles by Benjamin Kulovac
Articles by Osman Hadziosmanovic
on IndexScholar Fulltext
on Google
on Google Scholar
Article Statistics
 Viewed: 1306
Downloaded: 278
Cited: 1




 




» For Authors




Become Reviewer


» Login Area






Follow ScopeMed on Twitter

ScopeMed Home
Job Opportunities/Service Offers
About ScopeMed
Terms & Conditions
Privacy Policy
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of SAGEYA Publishing for Scientific Publications. Copyright © ScopeMed® International Medical Journal Management and Indexing System.